Humulin M3 (30/70) (Insulin Human (Rdna))

Humulin M3 (30/70) is a prescription, subcutaneous insulin product that contains human insulin produced by recombinant DNA technology. It is supplied as a premixed suspension containing 30 % soluble (regular) insulin and 70 % intermediate‑acting NPH insulin. The formulation is intended for subcutaneous injection and is marketed in the European Union for the management of diabetes mellitus in both type 1 and type 2 patients under medical supervision by qualified healthcare professionals.

Humulin M3 (30/70) is indicated for the control of blood glucose in adults with diabetes mellitus.

- Type 1 diabetes mellitus requiring basal and prandial insulin coverage. - Type 2 diabetes mellitus when oral agents and lifestyle measures are insufficient. - Patients who benefit from a fixed ratio of rapid‑acting and intermediate‑acting insulin. - Use in combination with dietary management and exercise to achieve target glycemic levels.

Adverse reactions to Humulin M3 (30/70) may vary in frequency and severity.

Common: - Hypoglycemia, especially if meals are missed or delayed. - Injection‑site pain, redness, or swelling. - Weight gain associated with improved glycemic control. - Lipodystrophy at repeated injection sites. - Mild edema.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions ranging from urticaria to anaphylaxis. - Hypokalemia secondary to rapid glucose shifts. - Insulin‑induced edema that may exacerbate heart failure. - Rare cases of insulin antibody formation causing unpredictable glucose control.

When prescribing Humulin M3 (30/70), clinicians should consider several safety factors.

- Assess risk of hypoglycemia and educate patients on recognizing symptoms. - Adjust doses during illness, reduced food intake, or increased physical activity. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Pregnancy category is unknown; weigh potential benefits against risks. - Monitor blood glucose regularly to avoid over‑correction. - Avoid use in individuals with known hypersensitivity to human insulin or any excipients. - Evaluate cardiovascular status, especially in patients prone to fluid retention.

Humulin M3 (30/70) can interact with other medicines that affect glucose metabolism or mask hypoglycemia.

Avoid: - Concomitant use of other insulin products or high‑dose sulfonylureas, which may precipitate severe hypoglycemia. - Beta‑adrenergic blockers that can blunt typical hypoglycemia warning signs. - High‑dose glucocorticoids, which antagonize insulin’s glucose‑lowering effect. - Thiazide diuretics that may increase blood glucose levels. - Alcohol excess, which can cause delayed hypoglycemia.

Use with caution: - Oral antidiabetic agents (e.g., metformin, DPP‑4 inhibitors) – monitor glucose closely. - ACE inhibitors or ARBs – may enhance insulin sensitivity. - Exercise – adjust insulin dose to prevent hypoglycemia. - Pregnancy – limited data; monitor maternal and fetal glucose closely. - Elderly patients – increased sensitivity to insulin, requiring lower doses.